Cochrane · systematic review · CD010362
Pharmacological interventions other than botulinum toxin for spasticity after stroke
Lindsay, C, Kouzouna, A, Simcox, C, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
StrokeAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
2
current version
GRADE rated
2
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 2 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Systemic antispasticity drugs compared with placebo for spasticity after stroke
Population: people with spasticity following stroke
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Indirect measure of spasticity Modified Ashworth Scale Systemic antispasticity drugs vs placebo | OR 1.66 [0.12, 15.38] | 2 studies · 160 participants | Very low Downgraded: risk of bias, inconsistency |
Adverse events Adverse events per participant Systemic antispasticity drugs vs placebo | RR 1.65 [1.12, 2.42] | 2 studies · 160 participants | Very low Downgraded: risk of bias |